UA130650C2 - Сіль і кристалічні форми інгібітора активін-рецептороподібної кінази - Google Patents
Сіль і кристалічні форми інгібітора активін-рецептороподібної кіназиInfo
- Publication number
- UA130650C2 UA130650C2 UAA202200733A UAA202200733A UA130650C2 UA 130650 C2 UA130650 C2 UA 130650C2 UA A202200733 A UAA202200733 A UA A202200733A UA A202200733 A UAA202200733 A UA A202200733A UA 130650 C2 UA130650 C2 UA 130650C2
- Authority
- UA
- Ukraine
- Prior art keywords
- salt
- compound
- peaks
- diffraction pattern
- sun
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
- C07C55/02—Dicarboxylic acids
- C07C55/10—Succinic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Physical Education & Sports Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962885977P | 2019-08-13 | 2019-08-13 | |
| PCT/US2020/045847 WO2021030386A1 (en) | 2019-08-13 | 2020-08-12 | Salt and crystal forms of an activin receptor-like kinase inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA130650C2 true UA130650C2 (uk) | 2026-04-08 |
Family
ID=72193669
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA202200733A UA130650C2 (uk) | 2019-08-13 | 2020-08-12 | Сіль і кристалічні форми інгібітора активін-рецептороподібної кінази |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220281879A1 (https=) |
| EP (1) | EP4013757A1 (https=) |
| JP (2) | JP7775186B2 (https=) |
| KR (1) | KR20220052955A (https=) |
| CN (2) | CN119638704A (https=) |
| BR (1) | BR112022002597A2 (https=) |
| CA (1) | CA3146701A1 (https=) |
| CO (1) | CO2022001450A2 (https=) |
| IL (1) | IL290482A (https=) |
| JO (1) | JOP20220014A1 (https=) |
| MX (2) | MX2022001741A (https=) |
| TW (1) | TWI870440B (https=) |
| UA (1) | UA130650C2 (https=) |
| WO (1) | WO2021030386A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311889B (zh) * | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
| EP3870181B1 (en) | 2018-10-26 | 2024-08-14 | Keros Therapeutics, Inc. | Crystal forms of an alk2 inhibitor |
| US12508262B2 (en) | 2020-04-30 | 2025-12-30 | Keros Therapeutics, Inc. | Methods of using ALK2 inhibitors |
| WO2022098812A1 (en) | 2020-11-04 | 2022-05-12 | Keros Therapeutics, Inc. | Methods of treating iron overload |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN109311889B (zh) * | 2016-04-15 | 2021-11-16 | 缆图药品公司 | 激活素受体样激酶抑制剂 |
| AR112027A1 (es) * | 2017-06-15 | 2019-09-11 | Biocryst Pharm Inc | Inhibidores de alk 2 quinasa que contienen imidazol |
-
2020
- 2020-08-12 TW TW109127433A patent/TWI870440B/zh active
- 2020-08-12 CN CN202411831775.3A patent/CN119638704A/zh active Pending
- 2020-08-12 US US17/633,440 patent/US20220281879A1/en active Pending
- 2020-08-12 UA UAA202200733A patent/UA130650C2/uk unknown
- 2020-08-12 EP EP20761085.8A patent/EP4013757A1/en active Pending
- 2020-08-12 CA CA3146701A patent/CA3146701A1/en active Pending
- 2020-08-12 JO JOP/2022/0014A patent/JOP20220014A1/ar unknown
- 2020-08-12 KR KR1020227008160A patent/KR20220052955A/ko active Pending
- 2020-08-12 BR BR112022002597A patent/BR112022002597A2/pt unknown
- 2020-08-12 MX MX2022001741A patent/MX2022001741A/es unknown
- 2020-08-12 JP JP2022508779A patent/JP7775186B2/ja active Active
- 2020-08-12 CN CN202080057092.0A patent/CN114222745B/zh active Active
- 2020-08-12 WO PCT/US2020/045847 patent/WO2021030386A1/en not_active Ceased
-
2022
- 2022-02-09 MX MX2024014312A patent/MX2024014312A/es unknown
- 2022-02-09 IL IL290482A patent/IL290482A/en unknown
- 2022-02-14 CO CONC2022/0001450A patent/CO2022001450A2/es unknown
-
2025
- 2025-07-04 JP JP2025113638A patent/JP2025148406A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022544272A (ja) | 2022-10-17 |
| CN114222745A (zh) | 2022-03-22 |
| BR112022002597A2 (pt) | 2022-07-05 |
| CN114222745B (zh) | 2025-03-25 |
| CA3146701A1 (en) | 2021-02-18 |
| WO2021030386A1 (en) | 2021-02-18 |
| CO2022001450A2 (es) | 2022-05-31 |
| CN119638704A (zh) | 2025-03-18 |
| AU2020328534A1 (en) | 2022-03-17 |
| JP2025148406A (ja) | 2025-10-07 |
| EP4013757A1 (en) | 2022-06-22 |
| IL290482A (en) | 2022-04-01 |
| KR20220052955A (ko) | 2022-04-28 |
| TWI870440B (zh) | 2025-01-21 |
| JOP20220014A1 (ar) | 2023-01-30 |
| MX2024014312A (es) | 2024-12-06 |
| TW202120509A (zh) | 2021-06-01 |
| JP7775186B2 (ja) | 2025-11-25 |
| US20220281879A1 (en) | 2022-09-08 |
| MX2022001741A (es) | 2022-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA130650C2 (uk) | Сіль і кристалічні форми інгібітора активін-рецептороподібної кінази | |
| ES2550771T3 (es) | Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas | |
| ES2685819T3 (es) | Formas mórficas de ésteres de hexadeciloxipropil-fosfonato | |
| WO1998039325A1 (en) | 4,4-difluoro-2,3,4,5-tetrahydro-1h-1-benzazepine derivatives and drug compositions containing them | |
| BR112014022790B1 (pt) | Sais de um inibidor de quinase de receptor de fator do crescimento epidermal, composição farmacêutica e usos do mesmo | |
| CA3154079A1 (en) | Therapeutic conjugates | |
| US8946249B2 (en) | Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use | |
| CN111566102A (zh) | 作为激活素受体样激酶抑制剂的取代的吡咯并吡啶 | |
| US20240228500A1 (en) | Therapeutic conjugates | |
| CA3184979A1 (en) | Immunomodulator | |
| JP2021526156A (ja) | ジメチルホスフィンオキシド化合物 | |
| CN111757877A (zh) | 甲基内酰胺环化合物及其药物用途 | |
| EA031569B1 (ru) | Солевые и кристаллические формы ингибитора plk-4 | |
| JP2021512964A (ja) | グランザイムｂ指向性画像化および治療 | |
| JP2019512542A (ja) | 結晶塩形態 | |
| BR112020016205A2 (pt) | Formas cocristalinas de prolina e de análogo de novobiocina | |
| US20250179049A1 (en) | Salts of heterocyclic inhibitors of monocarboxylate transporter 4 for the treatment of disease | |
| AU2020328534B2 (en) | Salt and crystal forms of an activin receptor-like kinase inhibitor | |
| CN104093703B (zh) | Mglu 2/3激动剂 | |
| RU2809634C2 (ru) | Соединение с метиллактамным кольцом и его применение в фармацевтике | |
| BRPI0620526A2 (pt) | sal de acetato e método para alcançar um efeito em um paciente | |
| HK40069001A (en) | Salt and crystal forms of an activin receptor-like kinase inhibitor | |
| TW202327576A (zh) | 吡咯烷類化合物的鹽、晶型及其製備方法 | |
| HK40117473A (zh) | 活化素受体样激酶抑制剂的盐和晶体形式 | |
| HK40069001B (zh) | 活化素受体样激酶抑制剂的盐和晶体形式 |